Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEITHO-3 reduced-dose thrombolysis trial for intermediate-high-risk acute pulmonary embolism
NL-OMON56449Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary embolism (PE) comparing Reduced-dose alteplase plus anticoagulation with Placebo plus anticoagulation (2 arms). Primary endpoint: Primary composite efficacy outcome. Planned start May 2022; status: not yet recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON56449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56449.